Diabetic kidney disease

Merlin C. Thomas, Michael Brownlee, Katalin Susztak, Kumar Sharma, Karin A.M. Jandeleit-Dahm, Sophia Zoungas, Peter Rossing, Per Henrik Groop, Mark E. Cooper

Research output: Contribution to journalReview article

62 Citations (Scopus)

Abstract

The kidney is arguably the most important target of microvascular damage in diabetes. A substantial proportion of individuals with diabetes will develop kidney disease owing to their disease and/or other co-morbidity, including hypertension and ageing-related nephron loss. The presence and severity of chronic kidney disease (CKD) identify individuals who are at increased risk of adverse health outcomes and premature mortality. Consequently, preventing and managing CKD in patients with diabetes is now a key aim of their overall management. Intensive management of patients with diabetes includes controlling blood glucose levels and blood pressure as well as blockade of the renin-angiotensin-aldosterone system; these approaches will reduce the incidence of diabetic kidney disease and slow its progression. Indeed, the major decline in the incidence of diabetic kidney disease (DKD) over the past 30 years and improved patient prognosis are largely attributable to improved diabetes care. However, there remains an unmet need for innovative treatment strategies to prevent, arrest, treat and reverse DKD. In this Primer, we summarize what is now known about the molecular pathogenesis of CKD in patients with diabetes and the key pathways and targets implicated in its progression. In addition, we discuss the current evidence for the prevention and management of DKD as well as the many controversies. Finally, we explore the opportunities to develop new interventions through urgently needed investment in dedicated and focused research. For an illustrated summary of this Primer, visit: http://go.nature.com/NKHDzg.

Original languageEnglish (US)
Article number15018
JournalNature Reviews Disease Primers
Volume1
DOIs
StatePublished - Jul 30 2015
Externally publishedYes

Fingerprint

Diabetic Nephropathies
Chronic Renal Insufficiency
Premature Mortality
Incidence
Nephrons
Kidney Diseases
Renin-Angiotensin System
Blood Glucose
Blood Pressure
Hypertension
Morbidity
Kidney
Health
Research
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., ... Cooper, M. E. (2015). Diabetic kidney disease. Nature Reviews Disease Primers, 1, [15018]. https://doi.org/10.1038/nrdp.2015.18

Diabetic kidney disease. / Thomas, Merlin C.; Brownlee, Michael; Susztak, Katalin; Sharma, Kumar; Jandeleit-Dahm, Karin A.M.; Zoungas, Sophia; Rossing, Peter; Groop, Per Henrik; Cooper, Mark E.

In: Nature Reviews Disease Primers, Vol. 1, 15018, 30.07.2015.

Research output: Contribution to journalReview article

Thomas, MC, Brownlee, M, Susztak, K, Sharma, K, Jandeleit-Dahm, KAM, Zoungas, S, Rossing, P, Groop, PH & Cooper, ME 2015, 'Diabetic kidney disease', Nature Reviews Disease Primers, vol. 1, 15018. https://doi.org/10.1038/nrdp.2015.18
Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S et al. Diabetic kidney disease. Nature Reviews Disease Primers. 2015 Jul 30;1. 15018. https://doi.org/10.1038/nrdp.2015.18
Thomas, Merlin C. ; Brownlee, Michael ; Susztak, Katalin ; Sharma, Kumar ; Jandeleit-Dahm, Karin A.M. ; Zoungas, Sophia ; Rossing, Peter ; Groop, Per Henrik ; Cooper, Mark E. / Diabetic kidney disease. In: Nature Reviews Disease Primers. 2015 ; Vol. 1.
@article{556211d49b2d44ecb5a734ed7c7cf2aa,
title = "Diabetic kidney disease",
abstract = "The kidney is arguably the most important target of microvascular damage in diabetes. A substantial proportion of individuals with diabetes will develop kidney disease owing to their disease and/or other co-morbidity, including hypertension and ageing-related nephron loss. The presence and severity of chronic kidney disease (CKD) identify individuals who are at increased risk of adverse health outcomes and premature mortality. Consequently, preventing and managing CKD in patients with diabetes is now a key aim of their overall management. Intensive management of patients with diabetes includes controlling blood glucose levels and blood pressure as well as blockade of the renin-angiotensin-aldosterone system; these approaches will reduce the incidence of diabetic kidney disease and slow its progression. Indeed, the major decline in the incidence of diabetic kidney disease (DKD) over the past 30 years and improved patient prognosis are largely attributable to improved diabetes care. However, there remains an unmet need for innovative treatment strategies to prevent, arrest, treat and reverse DKD. In this Primer, we summarize what is now known about the molecular pathogenesis of CKD in patients with diabetes and the key pathways and targets implicated in its progression. In addition, we discuss the current evidence for the prevention and management of DKD as well as the many controversies. Finally, we explore the opportunities to develop new interventions through urgently needed investment in dedicated and focused research. For an illustrated summary of this Primer, visit: http://go.nature.com/NKHDzg.",
author = "Thomas, {Merlin C.} and Michael Brownlee and Katalin Susztak and Kumar Sharma and Jandeleit-Dahm, {Karin A.M.} and Sophia Zoungas and Peter Rossing and Groop, {Per Henrik} and Cooper, {Mark E.}",
year = "2015",
month = "7",
day = "30",
doi = "10.1038/nrdp.2015.18",
language = "English (US)",
volume = "1",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Diabetic kidney disease

AU - Thomas, Merlin C.

AU - Brownlee, Michael

AU - Susztak, Katalin

AU - Sharma, Kumar

AU - Jandeleit-Dahm, Karin A.M.

AU - Zoungas, Sophia

AU - Rossing, Peter

AU - Groop, Per Henrik

AU - Cooper, Mark E.

PY - 2015/7/30

Y1 - 2015/7/30

N2 - The kidney is arguably the most important target of microvascular damage in diabetes. A substantial proportion of individuals with diabetes will develop kidney disease owing to their disease and/or other co-morbidity, including hypertension and ageing-related nephron loss. The presence and severity of chronic kidney disease (CKD) identify individuals who are at increased risk of adverse health outcomes and premature mortality. Consequently, preventing and managing CKD in patients with diabetes is now a key aim of their overall management. Intensive management of patients with diabetes includes controlling blood glucose levels and blood pressure as well as blockade of the renin-angiotensin-aldosterone system; these approaches will reduce the incidence of diabetic kidney disease and slow its progression. Indeed, the major decline in the incidence of diabetic kidney disease (DKD) over the past 30 years and improved patient prognosis are largely attributable to improved diabetes care. However, there remains an unmet need for innovative treatment strategies to prevent, arrest, treat and reverse DKD. In this Primer, we summarize what is now known about the molecular pathogenesis of CKD in patients with diabetes and the key pathways and targets implicated in its progression. In addition, we discuss the current evidence for the prevention and management of DKD as well as the many controversies. Finally, we explore the opportunities to develop new interventions through urgently needed investment in dedicated and focused research. For an illustrated summary of this Primer, visit: http://go.nature.com/NKHDzg.

AB - The kidney is arguably the most important target of microvascular damage in diabetes. A substantial proportion of individuals with diabetes will develop kidney disease owing to their disease and/or other co-morbidity, including hypertension and ageing-related nephron loss. The presence and severity of chronic kidney disease (CKD) identify individuals who are at increased risk of adverse health outcomes and premature mortality. Consequently, preventing and managing CKD in patients with diabetes is now a key aim of their overall management. Intensive management of patients with diabetes includes controlling blood glucose levels and blood pressure as well as blockade of the renin-angiotensin-aldosterone system; these approaches will reduce the incidence of diabetic kidney disease and slow its progression. Indeed, the major decline in the incidence of diabetic kidney disease (DKD) over the past 30 years and improved patient prognosis are largely attributable to improved diabetes care. However, there remains an unmet need for innovative treatment strategies to prevent, arrest, treat and reverse DKD. In this Primer, we summarize what is now known about the molecular pathogenesis of CKD in patients with diabetes and the key pathways and targets implicated in its progression. In addition, we discuss the current evidence for the prevention and management of DKD as well as the many controversies. Finally, we explore the opportunities to develop new interventions through urgently needed investment in dedicated and focused research. For an illustrated summary of this Primer, visit: http://go.nature.com/NKHDzg.

UR - http://www.scopus.com/inward/record.url?scp=85017272654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017272654&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2015.18

DO - 10.1038/nrdp.2015.18

M3 - Review article

VL - 1

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 15018

ER -